What does NEUROPRAKT do?

NEUROPRAKT is a specialist medical practice in Hasselt. Private Limited, started on 29 July 1996, 1 establishment.

What is the address of NEUROPRAKT?

The registered office of NEUROPRAKT is located at Sint-Martinusplein 4B, 3500 Hasselt.

Is NEUROPRAKT still active?

Yes. According to the CBE (31 October 2026) NEUROPRAKT is active, legal situation “Normale toestand”, started on 29 July 1996.

Is NEUROPRAKT registered on Peppol?

Yes, NEUROPRAKT is registered on the Peppol network with ID 0208:0458571458.

What is the enterprise number of NEUROPRAKT?

The enterprise number of NEUROPRAKT is BE0458571458.

When was NEUROPRAKT founded?

NEUROPRAKT was founded on 29 July 1996.

Is NEUROPRAKT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 July 1996; 5 annual accounts filed, latest fiscal year 2025; 7 directors known from the annual account.

How much profit did NEUROPRAKT make in 2025?

NEUROPRAKT recorded a loss after taxes of € 0 in financial year 2025.

What is the revenue of NEUROPRAKT?

As a small company, NEUROPRAKT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 189,009.

Does NEUROPRAKT have a website?

Yes, NEUROPRAKT has a website at neurologiehasselt.be.

NEUROPRAKT (Private Limited) - Hasselt - BE0458571458

Q: Who are the directors of NEUROPRAKT?

According to the 2025 annual accounts, the directors of NEUROPRAKT are: Koen Delmotte, Sylvia Hermans, Isabel Dhollander, Peter Soors, Karlien Reekmans, Martin Herklots, Nina De Klippel.

Dossier NEUROPRAKT, printed on 1 November 2026 from databakkes.be/en/0458571458/neuroprakt. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

NEUROPRAKT from Hasselt, company number BE0458571458, closed financial year 2025 with a result of € -0 after tax. For that financial year NEUROPRAKT recorded a gross margin of € 189,009 and equity of € 33,296. Compared with financial year 2024, the result moved from € -14,830 to € -0. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Healthy

€ 33,296

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -0

▲ 100 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 94,143

▲ € 87,291 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 27,098.

People and assets in 2025

Wage cost

€ 138,949

▲ 103% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,356

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 260,337

€ 22,440 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 132,682

▲ € 125,686 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 23,376

▲ 121% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 50,324 Gross margin 2022: € 50,324 First fiscal year in the series	€ 54,924 Gross margin 2023: € 54,924 ▲ 9% vs 2022 (€ 50,324) Favourable step	€ 59,869 Gross margin 2024: € 59,869 ▲ 9% vs 2023 (€ 54,924) Favourable step	€ 189,009 Gross margin 2025: € 189,009 ▲ 216% vs 2024 (€ 59,869) Favourable step	▲ 216%
Profit after taxes	€ -5,529 Profit after taxes 2022: € -5,529 First fiscal year in the series	€ -488 Profit after taxes 2023: € -488 ▲ € 5,042 vs 2022 (€ -5,529) Favourable step	€ -14,830 Profit after taxes 2024: € -14,830 ▼ € 14,342 vs 2023 (€ -488) Unfavourable step	€ -0 Profit after taxes 2025: € -0 ▲ € 14,830 vs 2024 (€ -14,830) Favourable step	▲ € 14,830
Equity	€ 48,613 Equity 2022: € 48,613 First fiscal year in the series	€ 48,125 Equity 2023: € 48,125 ▼ 1% vs 2022 (€ 48,613) Unfavourable step	€ 33,296 Equity 2024: € 33,296 ▼ 31% vs 2023 (€ 48,125) Unfavourable step	€ 33,296 Equity 2025: € 33,296 Unchanged (€ 33,296) Unfavourable step
Total debts	€ 31,860 Total debts 2022: € 31,860 First fiscal year in the series	€ 19,551 Total debts 2023: € 19,551 ▼ 39% vs 2022 (€ 31,860) Favourable step	€ 25,212 Total debts 2024: € 25,212 ▲ 29% vs 2023 (€ 19,551) Unfavourable step	€ 559,309 Total debts 2025: € 559,309 ▲ € 534,098 vs 2024 (€ 25,212) Unfavourable step	▲ € 534,098
Cash	€ 68,075 Cash 2022: € 68,075 First fiscal year in the series	€ 5,581 Cash 2023: € 5,581 ▼ 92% vs 2022 (€ 68,075) Unfavourable step	€ 6,853 Cash 2024: € 6,853 ▲ 23% vs 2023 (€ 5,581) Favourable step	€ 94,143 Cash 2025: € 94,143 ▲ € 87,291 vs 2024 (€ 6,853) Favourable step	▲ € 87,291
Land & buildings	€ 9,016 Land & buildings 2022: € 9,016 First fiscal year in the series	€ 9,016 Land & buildings 2023: € 9,016 Unchanged (€ 9,016) Unchanged	€ 9,016 Land & buildings 2024: € 9,016 Unchanged (€ 9,016) Unchanged	€ 310,280 Land & buildings 2025: € 310,280 ▲ € 301,264 vs 2024 (€ 9,016) Unchanged	▲ € 301,264
Retained profit	€ 42,416 Retained profit 2022: € 42,416 First fiscal year in the series	€ 41,928 Retained profit 2023: € 41,928 ▼ 1% vs 2022 (€ 42,416) Unfavourable step	€ 27,098 Retained profit 2024: € 27,098 ▼ 35% vs 2023 (€ 41,928) Unfavourable step	€ 27,098 Retained profit 2025: € 27,098 Unchanged (€ 27,098) Unfavourable step
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 260,337 Bank debt 2025: € 260,337 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 80,473 Balance sheet total 2022: € 80,473 First fiscal year in the series	€ 67,677 Balance sheet total 2023: € 67,677 ▼ 16% vs 2022 (€ 80,473) Unchanged	€ 58,507 Balance sheet total 2024: € 58,507 ▼ 14% vs 2023 (€ 67,677) Unchanged	€ 592,605 Balance sheet total 2025: € 592,605 ▲ € 534,098 vs 2024 (€ 58,507) Unchanged	▲ € 534,098

Key figures of NEUROPRAKT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to NEUROPRAKT?

What happened at NEUROPRAKT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: loss of € 0. filed late Source: NBB ↗
Aug 9, 1996 New establishment in Hasselt. KBO
Jul 29, 1996 Start of the company according to the CBE. KBO

In short

From € 5,529 loss in 2022 to € 0 loss in 2025.

Original PDFs at the National Bank ↗

Management

Neuromeer 20%

DR. HERMANS SYLVIA 14.3%

DR. Dhollander Isabel 14.3%

dr. K. Reekmans, neurologie 14.3%

The stake of Neuromeer, DR. HERMANS SYLVIA, DR. Dhollander Isabel, dr. K. Reekmans, neurologie, DR. DELMOTTE KOEN, NEUROLOGIE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

NEUROPRAKT

Behind NEUROPRAKT are Koen Delmotte, Sylvia Hermans, Isabel Dhollander, Peter Soors, Karlien Reekmans and Martin Herklots. The shares are held by Neuromeer (20%), DR. HERMANS SYLVIA (14.3%), DR. Dhollander Isabel (14.3%), dr. K. Reekmans, neurologie (14.3%) and DR. DELMOTTE KOEN, NEUROLOGIE (14%).

Directors

According to the 2025 annual accounts

Koen Delmotte

Director

Also active at: DR. DELMOTTE KOEN, NEUROLOGIE

Sylvia Hermans

Director

Also active at: DR. HERMANS SYLVIA

Isabel Dhollander

Director

Also active at: DR. Dhollander Isabel

Peter Soors

Director

Also active at: DOKTERSVENNOOTSCHAP SOORS - LIEBEN

Karlien Reekmans

Director

Also active at: dr. K. Reekmans, neurologie

Martin Herklots

Director

Also active at: Neuromeer

Nina De Klippel

Director

Shareholders

Neuromeer

20%

DR. HERMANS SYLVIA

14.3%

DR. Dhollander Isabel

14.3%

dr. K. Reekmans, neurologie

14.3%

DR. DELMOTTE KOEN, NEUROLOGIE

14%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Sint-Martinusplein 4B

3500 Hasselt

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS neurologiehasselt.be

Canonical: https://www.neurologiehasselt.be/

Technologies

ASP.NETNginxPHPPlausible

Hosting & Email

Email provider

Self-hosted

Hosting

GOOGLE-CLOUD-PLATFORM - Google LLC, US

Website info

HTTPS Ja

Languages NL

Features

Webshop Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Details

Company number: 0458.571.458
VAT number: BE 0458.571.458
Registered office: Sint-Martinusplein 4B, 3500 Hasselt
Names & denominations: NEUROPRAKT
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 29 July 1996
Peppol: Active · Active since 17 Mar 2026
Contact: neurologiehasselt.be +3211241214
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗

NEUROPRAKT

Warning lights

Financials

What happened to NEUROPRAKT?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions